Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. Co. has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. The MBIO average annual return since 2017 is shown above.
The Average Annual Return on the MBIO average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MBIO average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free MBIO Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
